Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer based in Jerusalem, Israel, covers the month of March 2019. The report, dated March 7, 2019, consists solely of a press release regarding a corporate governance update.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a personnel change and does not contain financial statements or operational metrics.
Material Changes
The material change disclosed in this filing is a transition in the Chief Financial Officer (CFO) position. No financial or operational changes relative to prior periods are detailed in this document.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the announcement of the CFO transition.
Key Facts for Investor Verification
- The company announced a transition in its Chief Financial Officer position on March 7, 2019.
- The report was signed by Dr. Phillip Schwartz, Chief Executive Officer.
- No financial data or operational updates are included in this specific filing.